Abstract:
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
Abstract:
The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
Abstract:
The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
Abstract:
The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
Abstract:
The present invention relates to chemical compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR).
Abstract:
The present disclosure relates to quinoline compounds of formula I, compositions comprising them and methods and uses for the treatment of central nervous system disorders, such as mood disorders (eg. depression), anxiety disorders, and neurodegenerative diseases. Additionally, the disclosure relates to methods of enhancing neurite outgrowth and the treatment of diseases/conditions associated with neurite outgrowth (eg. multiple sclerosis).